Last reviewed · How we verify
NCT06914570: CIED-REMTRIC
Cardiac Implantable Electronic Device- Induced Remodelling of Tricuspid Valve and Right Chambers
trial in Cardiac Pacing, Artificial in 350 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Istituto Auxologico Italiano |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 1 May 2024 |
| Primary completion | 1 May 2026 |
| Estimated completion | 24 February 2029 |
| Sites | 1 location across Italy |
Conditions studied
- Cardiac Pacing, Artificial — all drugs for Cardiac Pacing, Artificial →
- Tricuspid Valve Regurgitation, Non-rheumatic — all drugs for Tricuspid Valve Regurgitation, Non-rheumatic →
Sponsor
Istituto Auxologico Italiano — full company profile →
Who can join
18 and older, any sex, with Cardiac Pacing, Artificial or Tricuspid Valve Regurgitation, Non-rheumatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-center longitudinal study aims to evaluate the occurrence and clinical impact of tricuspid regurgitation (TR) after cardiac-implanted-electronic-device (CIED) implantation by comprehensive echocardiographic assessment, including advanced three-dimensional (3D) transthoracic and transesophageal imaging. The primary objective of this study is to assess the prevalence and leading mechanism of new or worsening TR, defined as an increase of at least one grade on a five-grade scale, after new CIED implantation. Secondary objectives include clinical and echocardiographic endpoints at discharge, three months, one year, and annually for up to five years. They can be summarized as follows: 1. to evaluate morphological and functional changes (remodeling) of the tricuspid valve (TV) apparatus and right-sided heart chambers in patients undergoing new CIED implantation. 2. to identify risk factors for new or worsening TR after CIED implantation on an anatomical, procedural, and clinical level. 3. to determine the clinical impact of new or worsening TR after CIED implantation. 4. to explore the treatment strategies for lead-related TR (observational).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06914570
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Istituto Auxologico Italiano trials
Trials by the same sponsor.
- NCT07384962 — ORION Study: Mesh Position and Risk During Subsequent Minimally Invasive Abdominal Surgery · not yet recruiting
- NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease · NA · recruiting
- NCT07302321 — Needs of ALS Patients With C9orf72 Mutation and Their Caregivers · recruiting
- NCT07162740 — Implantable Loop Recorder and Cardioneuroblation · not yet recruiting
- NCT07312240 — LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06914570 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Auxologico Italiano
- Last refreshed: 6 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06914570.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing